Finland· FI-REL-REL53660
Levopidon
A levomethadone product containing levomethadone hydrochloride, registered in Finland by Navamedic ASA. The same ATC class is registered in 6 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Levomethadone is registered in 6 of 19 countries.
Countries holding a registration under ATC N07BC05 (levomethadone), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 4 of them publish a price we can compare per daily dose
Levomethadone · ATC N07BC05
6 / 19 countries
- Denmark
- Finlandprice
- Germany
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of levomethadone costs, country by country.
Normalised to the WHO defined daily dose (15 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Levomethadone · price per daily dose (15 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.73
The record
At a glance
Fimea (Finland)- Active substance
- Levomethadone hydrochloride
- Manufacturer
- Navamedic ASA
- Country
- Finland (FI)
- ATC code
- N07BC05
- ATC class
- Levomethadone
- Defined daily dose
- 15 mg, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
6 interactions on record for levomethadone.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Levomethadone · interactions on record
6 records
6 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Levomethadone in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenLevopidon 2,5 mg TablettNavamedic ASA
- NorwayLevopidonNavamedic ASA
- GermanyL-PoladdictHexal Ag
- SwitzerlandL-Polamidon 5 mg/mL, Lösung zum EinnehmenSandoz Pharmaceuticals AG
- PolandLefisyoINN-FARM d.o.o.,
- SpainLEVOMETADONA MOLTENI 5 MG/ML SOLUCION ORALL. Molteni & C. Dei Fratelli Alitti Societa Di Esercizio S.P.A.
Authorised across Europe · EMA
The same active substance is authorised in 13 EEA countries. Names it is sold under:
- Austria · L-Polamidon, Lefisyo
- Bulgaria · Лефисио
- Germany · L-Poladdict, L-Polaflux
- Denmark · Levopidon
- Spain · Levometadona Molteni
- Croatia · Lefisyo
- Hungary · Lefisyo
- Italy · Agovadin, Ellepalmiron
- Norway · Levopidon
- Poland · Lefisyo, Levomethadone Hydrochloride Molteni
- Romania · Lefisyo
- Sweden · Levopidon
- Slovenia · Lefisyo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b56ad475-d96e-4d94-b090-1d2d8fa3178e GET /v1/drugs/b56ad475-d96e-4d94-b090-1d2d8fa3178e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "15",
"form": "tabletti",
"route": "Suun kautta",
"ddd_unit": "mg",
"strength": "2.5 mg",
"atc_label": "levometadoni",
"ma_number": "36511",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL53660",
"authorised_at": "2020-03-06"
}See everything about levomethadone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.